Polycystic Kidney Disease Therapeutics Analysis and Other Developments

Press Release

Polycystic kidney disease therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Polycystic kidney disease (PKD) is a genetic disorder that primarily affects kidneys. It causes fluid-filled cysts to grow inside the kidneys, which increase the size and damage tissues of the kidneys. Symptoms of the disease include abdomen and back pain, urinary tract infection, frequent urination, blood in urine, kidney stones, and others. There are mainly two types of PKD: autosomal dominant PKD (ADPKD) and autosomal recessive PKD (ARPKD). The main reason for the disease is spontaneous mutation in PKD1, PKD2, and PKHD1 genes. These genes encode protein products polycystin-1 (PC1) and polycystin-2 (PC2 or TRPP2) that are responsible for normal kidney development, function, and organization. Therefore, mutation in these genes can lead to PKD.

Inquiry Before Purchase at: https://www.pharmaproff.com/enquiry/1245

It has been observed that many pharmaceutical companies are developing new and improved technologies and going into partnerships or acquiring other companies for the development of PKD therapeutics. For instance, in September 2018, Otsuka Holdings Co. Ltd. acquired Visterra Inc. to expand its portfolio and to develop better therapeutics for PKD.

Otsuka Holdings Co. Ltd., Exelixis Incorporated, Palladio Biosciences, XORTX Pharma Corp., Reata Pharmaceuticals Inc., and others are involved in the development of therapeutics for PKD.

PKD Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This post was originally published on Financial Sector

Comments are closed.